ストックスクリーナーアプリを入手
0.108
1.82%
-0.002
Cns Pharmaceuticals Inc (CNSP) 最新ニュース
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
Does Cns Pharmaceuticals Inc (NASDAQ: CNSP) Still Need To Convince Analysts? - Stocks Register
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
CNS Pharmaceuticals Announces Upcoming Virtual Analyst and Investor Day - Defense World
Cns Pharmaceuticals Inc (NASDAQ: CNSP): An Enticing Stock To Watch - Stocks Register
CNS Pharmaceuticals Hosts Virtual Analyst and Investor Day - Nasdaq
CNS Pharmaceuticals (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11 - Barchart
CNS Pharmaceuticals sets date for virtual investor event By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 - AccessWire
CNS Pharmaceuticals gains shareholder nod for reverse split, warrant repricing - Investing.com
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - AccessWire
CNS Pharma's Berubicin Shows Higher Patient Retention in Pivotal GBM Trial | CNSP Stock News - StockTitan
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma - Barchart
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - GuruFocus.com
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 4.3% – Here’s What Happened - Defense World
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting - Barchart
CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin - Barchart
CNS Pharmaceuticals to Present Berubicin GBM Trial Data at SNO 2024 Annual Meeting | CNSP Stock News - StockTitan
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - AccessWire
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results - AccessWire
CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan
CNS Pharmaceuticals Inc (CNSP) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in CNS Pharmaceuticals Inc - GuruFocus.com
CNS Pharmaceuticals: Financial Results and Strategic Moves - TipRanks
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com
CNS Pharmaceuticals’ $3 Million Common Stock Offering - Global Legal Chronicle
Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - AccessWire
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Berubicin’s Potential During KOL Connect Event - Barchart
CNS Pharmaceuticals Receives Temporary Exception from NASDAQ Regarding Minimum Bid Price Requirement - Defense World
CNS Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com South Africa
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Yahoo Finance
CNS Pharmaceuticals granted Nasdaq compliance extension - Investing.com
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - Financial Content
CNS Pharmaceuticals faces NASDAQ delisting over price rule By Investing.com - Investing.com Australia
CNS Pharmaceuticals secures $3 million in registered direct offering - Investing.com
CNS Pharmaceuticals secures $3 million in registered direct offering By Investing.com - Investing.com UK
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - AccessWire
CNS Pharmaceuticals faces NASDAQ delisting over price rule - Investing.com
Stock Performance Spotlight: Cns Pharmaceuticals Inc (CNSP) Ends the Day at 0.12, Up by 0.77 - The Dwinnex
Can you still get a good price for Cns Pharmaceuticals Inc (CNSP) Shares at this point? - US Post News
CNS Pharmaceuticals (NASDAQ: CNSP) Management Participates In Virtual Investor KOL Connect Segment - Barchart
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum - MSN
It is Poised to be a Bull Market for Cns Pharmaceuticals Inc (CNSP) - SETE News
Ladenburg Thalmann gives a Neutral recommendation for Cns Pharmaceuticals Inc (CNSP) - Knox Daily
Cns Pharmaceuticals Inc (CNSP) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):